Close

Sarepta Therapeutics (SRPT) Eteplirsen Dosing Said Delayed Until Oct./Nov.

September 19, 2014 3:15 PM EDT

(Updated - September 19, 2014 3:23 PM EDT)

Sarepta Therapeutics (NASDAQ: SRPT) eteplirsen trial start delay until Oct./Nov., according to the Boston Business Journal.

UPDATE - Sarepta CEO Chris Garabedian previously said the eteplirsen trial would begin in September. The firm has already begun enrolling50 to 80 patients.

Eteplirsen is a proposed treatment for Duchenne muscular dystrophy (DMD).

During an interview today, Garabedian said Initiating five new treatment studies requires a significant effort to prepare, and we’re doing all of this as fast as we can .. There's a lot that we're trying to accomplish in a short period of time.

News comes as Prosensa Holding N.V. (Nasdaq: RNA) announced earlier this week that a comprehensive program of re-dosing has commenced, with the first patients now re-dosed in the United States. All dosing in the drisapersen clinical program had been placed on hold by GSK on September 20, 2013, upon announcement of the DEMAND III study results.

Sarepta is down 4 percent Friday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Insiders' Blog, Management Comments, Rumors